efrat

Feb 2nd 2024- Dr. Paula Rodriguez-Otero- The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended marketing authorization approval for idecabtagene vicleucel (Abecma; ide-cel) for use in adult patients with relapsed and refractory multiple myeloma who previously received at least 2 therapies, including an immunomodulatory drug (IMiD), a proteasome inhibitor (PI), and an anti-CD38 monoclonal antibody

By efrat|2024-02-02T07:23:05+00:00February 2nd, 2024|All|Comments Off on Feb 2nd 2024- Dr. Paula Rodriguez-Otero- The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended marketing authorization approval for idecabtagene vicleucel (Abecma; ide-cel) for use in adult patients with relapsed and refractory multiple myeloma who previously received at least 2 therapies, including an immunomodulatory drug (IMiD), a proteasome inhibitor (PI), and an anti-CD38 monoclonal antibody

Read More

Jan 23rd 2024- Prof. Daniel Wolff- Safety and Efficacy of Axatilimab at 3 Different Doses in Patients with CGVHD Disease (AGAVE-201)

By efrat|2024-01-21T08:20:40+00:00January 22nd, 2024|All|Comments Off on Jan 23rd 2024- Prof. Daniel Wolff- Safety and Efficacy of Axatilimab at 3 Different Doses in Patients with CGVHD Disease (AGAVE-201)

Read More

Jan 8th 2024- David Valcarcel & Adrian Mosquera- Machine Learning Improves Risk Stratification in Myelodysplastic Neoplasms: An Analysis of the Spanish Group of Myelodysplastic Syndromes

By efrat|2024-01-07T07:28:24+00:00January 6th, 2024|All|Comments Off on Jan 8th 2024- David Valcarcel & Adrian Mosquera- Machine Learning Improves Risk Stratification in Myelodysplastic Neoplasms: An Analysis of the Spanish Group of Myelodysplastic Syndromes

Read More

Dec 19th 2023- Prof. Florent Malard- Gut Microbiota Diversity Before Allogeneic Hematopoietic Stem Cell Transplantation as a Predictor of Mortality in Children

By efrat|2023-12-13T10:37:16+00:00December 18th, 2023|All|Comments Off on Dec 19th 2023- Prof. Florent Malard- Gut Microbiota Diversity Before Allogeneic Hematopoietic Stem Cell Transplantation as a Predictor of Mortality in Children

Read More

Dec 12th 2023- Prof. Arnold Ganser – How I Treat Refractory and Relapsed Acute Myeloid Leukemia

By efrat|2023-12-06T07:49:31+00:00December 11th, 2023|All|Comments Off on Dec 12th 2023- Prof. Arnold Ganser – How I Treat Refractory and Relapsed Acute Myeloid Leukemia

Read More

Dec 5th 2023- Prof. Wolfgang Bethge- Outcomes of Axicabtagene Ciloleucel in PMBCL Compare Favorably with those in DLBCL: a GLA/DRST Registry Study

By efrat|2023-12-03T08:05:44+00:00December 4th, 2023|All|Comments Off on Dec 5th 2023- Prof. Wolfgang Bethge- Outcomes of Axicabtagene Ciloleucel in PMBCL Compare Favorably with those in DLBCL: a GLA/DRST Registry Study

Read More

Nov 28th 2023- Prof. Ibrahim Yakoub-Agha- Nonrelapse Mortality After CAR T-cell Therapy for Large B-cell Lymphoma: a LYSA Study from the DESCAR-T Registry

By efrat|2023-11-21T11:16:59+00:00November 27th, 2023|All|Comments Off on Nov 28th 2023- Prof. Ibrahim Yakoub-Agha- Nonrelapse Mortality After CAR T-cell Therapy for Large B-cell Lymphoma: a LYSA Study from the DESCAR-T Registry

Read More

Nov 21st 2023- Prof. Moshe Mittelman- A Randomized Comparison of CPX-351 and FLAG-Ida in Adverse Karyotype AML and High-Risk MDS: The UK NCRI AML19 Trial

By efrat|2023-11-19T06:54:42+00:00November 20th, 2023|All|Comments Off on Nov 21st 2023- Prof. Moshe Mittelman- A Randomized Comparison of CPX-351 and FLAG-Ida in Adverse Karyotype AML and High-Risk MDS: The UK NCRI AML19 Trial

Read More

Nov 14th 2023- Dr. Bipin Savani- Vitamin C and D Supplementation in Acute Myeloid Leukemia

By efrat|2023-11-08T06:35:37+00:00November 13th, 2023|All|Comments Off on Nov 14th 2023- Dr. Bipin Savani- Vitamin C and D Supplementation in Acute Myeloid Leukemia

Read More

Nov 6th 2023- Prof. Attilio Olivieri- Incidence, Clinical Presentation, Risk Factors, Outcomes, and Biomarkers in De Novo Late Acute GVHD

By efrat|2023-11-05T06:48:14+00:00November 4th, 2023|All|Comments Off on Nov 6th 2023- Prof. Attilio Olivieri- Incidence, Clinical Presentation, Risk Factors, Outcomes, and Biomarkers in De Novo Late Acute GVHD

Read More